Muscle Growth Research
Investigating satellite cell activation and hypertrophic signalling in skeletal muscle
What Is This Category?
Muscle growth peptide research focuses on compounds that stimulate the body's own muscle-building pathways — particularly the IGF-1/mTOR signalling axis and satellite cell activation. IGF-1 LR3 is a long-acting form of Insulin-like Growth Factor 1, a hormone naturally produced in the liver that drives muscle protein synthesis and satellite cell (muscle stem cell) proliferation. TB-500, also studied in the healing category, contributes here through its role in directing satellite cells to repair sites and improving blood supply to muscle tissue. These peptides are studied by researchers interested in skeletal muscle biology, hypertrophy mechanisms, and post-injury muscle recovery.
What People Research This For
- →Studying satellite cell (muscle stem cell) activation and proliferation
- →Muscle hypertrophy and protein synthesis pathway research
- →Post-injury muscle recovery combined with BPC-157 or TB-500
- →Lean body composition improvement in animal models
- →Resistance exercise biology and overload adaptation research
Pros & Cons
Effects Timeline
Based on published study timelines. Human extrapolation is approximate — individual results vary.
Satellite cell activation (Pax7+/BrdU+ staining) is detectable within 7–14 days in published animal models. Measurable increases in muscle fibre cross-sectional area typically require 4–6 weeks of treatment in rodent studies.
Scientific Overview
Muscle growth research focuses on peptides that engage the IGF-1/mTOR axis and thymosin-mediated actin dynamics to promote skeletal muscle hypertrophy, satellite cell proliferation, and post-exercise recovery. IGF-1 LR3 is a long-acting analogue of Insulin-like Growth Factor 1 with reduced insulin-receptor binding affinity, making it a useful research tool for isolating anabolic signalling pathways. TB-500 is included in this category due to its role in satellite cell migration and muscle fibre repair.
Mechanism of Action
IGF-1 LR3 activates the PI3K/Akt/mTOR pathway, driving protein synthesis and inhibiting muscle protein breakdown via FOXO3a suppression. Concurrently, it stimulates satellite cell proliferation via the MAPK/ERK cascade. TB-500 facilitates satellite cell homing to injury sites by upregulating actin polymerisation, enabling directed cell migration essential for myofibril repair.
Administration Methods
Reconstitute lyophilised powder in 0.1% acetic acid (0.6 mg/mL), then dilute to working concentration with sterile PBS. Aliquot and freeze at −20 °C; avoid repeated freeze-thaw cycles.
20–100 µg/mL
SC injection provides slower, more sustained absorption compared to IM. Preferred for chronic dosing studies.
Reconstitute in 1 mL BAC water. IM injection directly into the target muscle (e.g., gastrocnemius) concentrates peptide at the injury or study site.
500 µg/mL
IM TB-500 is used in satellite cell activation studies where local muscle depot is required.
Research Protocols
Muscle fibre cross-sectional area (CSA) via immunofluorescence, myosin heavy chain isoform expression, p70S6K phosphorylation (Western blot)
Satellite cell count (Pax7+/MyoD+ immunostaining), BrdU incorporation, myofibril fusion index
Key Published Studies
IGF-I splice variants and muscle hypertrophy
2003Mechano Growth Factor (MGF), an IGF-1 splice variant expressed after mechanical loading, demonstrated potent satellite cell activation with hypertrophic effects superior to systemic IGF-1 in a rodent overload model.
Long-acting IGF-1 analogue (IGF-1 LR3) increases muscle mass in vivo
1999IGF-1 LR3 produced a 20–30% increase in lean body mass compared to equimolar native IGF-1, attributed to its reduced binding to IGFBPs and consequently prolonged receptor engagement.
Expected Outcomes
Based on the weight of published preclinical evidence. Outcomes may vary depending on model, dose, and administration route.
- ✓Increased skeletal muscle fibre CSA (hypertrophy) measurable by immunofluorescence
- ✓Elevated p70S6K and 4E-BP1 phosphorylation (mTOR activation markers)
- ✓Enhanced satellite cell proliferation (Pax7+/BrdU+ cells)
- ✓Increased lean body mass by DXA or wet muscle weight
- ✓Reduced muscle protein degradation markers (MAFbx/atrogin-1, MuRF-1 mRNA)
Safety Considerations
- ⚠IGF-1 LR3 can cause hypoglycaemia at supraphysiological doses; blood glucose monitoring is recommended.
- ⚠Acetic acid reconstitution must be pH-adjusted before injection to avoid tissue damage.
- ⚠IGF-1 analogues carry theoretical oncogenic risk due to receptor promiscuity — dose and duration should be minimised.
- ⚠Not approved for human use. All experiments require appropriate ethics approval.
Frequently Asked Questions
Why use IGF-1 LR3 instead of native IGF-1?
IGF-1 LR3 has an arginine substitution at position 3 that dramatically reduces its affinity for IGF-binding proteins (IGFBPs). This extends its half-life from ~10 minutes to ~20 hours, making it far more practical for in vivo dosing studies without continuous infusion.
What is the role of TB-500 in muscle growth research?
TB-500 does not directly stimulate protein synthesis, but it facilitates satellite cell migration to sites of muscle damage and promotes angiogenesis, thereby improving the microenvironmental conditions for muscle repair and hypertrophic remodelling.
Practical Notes for Self-Researchers
Why must IGF-1 LR3 be reconstituted in acetic acid, not bacteriostatic water?
IGF-1 LR3 is poorly soluble at neutral pH. Dilute acetic acid (0.1%) lowers pH to solubilise the peptide. However, the acidic solution must be diluted with sterile PBS to physiological pH before injection — injecting the acetic acid solution undiluted causes significant tissue irritation and necrosis at the injection site.
Is IGF-1 LR3 the same as synthetic IGF-1?
No. IGF-1 LR3 has a modified arginine substitution at position 3 and an extended N-terminal sequence that dramatically reduces its binding to IGF-binding proteins (IGFBPs). This prevents the rapid clearance that limits native IGF-1's half-life to ~10 minutes, extending IGF-1 LR3's half-life to approximately 20 hours. The result is prolonged receptor activation from a single dose.
Source Peptides for Your Research
Compare Australian peptide vendors on purity, testing, domestic warehouse availability, and price per mg.